Dataset opportunity
Abilitypharma — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Abilitypharma, usable for Diagnostic AI and Computer Vision.
Score
67.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging Market size is expected to be worth around US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
Publication of clinical stage drug effects in glioblastoma models
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Abilitypharma holds a high-value, multi-jurisdictional Medical Imaging Dataset in Image modality, sourced from clinical trials across Spain, the USA, France, and Israel. This curated collection, supported by corresponding medical records and regulatory filings, provides the diverse, high-quality data essential for training and validating robust Diagnostic AI algorithms. The dataset's structure and associated documentation make it directly applicable for developing novel diagnostic tools.
This data is positioned to capitalize on the booming AI in Medical Imaging market, which was valued at US$ 1.70 billion in 2024 and is projected to grow at a remarkable CAGR of 25.8%. [7] While access is complex—requiring strict GDPR compliance for patient health information, multi-jurisdictional legal review, and management of intellectual property tied to proprietary R&D data—the rarity and direct clinical relevance of this dataset offer a significant competitive advantage in this high-growth sector. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data involves sensitive patient health information (PHI) requiring strict GDPR compliance.; Data is generated across multiple international sites (Spain, USA, France, Israel), necessitating multi-jurisdictional legal review.; Proprietary R&D data is tied to drug patents and intellectual property protections. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Abilitypharma holds a proprietary medical imaging dataset from a completed Phase 2b clinical trial involving 140 patients with metastatic pancreatic cancer. For diagnostic AI firms, this represents a rare opportunity to acquire high-quality, structured data essential for training and validating algorithms targeting a specific, high-need oncology indication. In a global AI medical imaging market projected to grow at over 25% annually, this dataset provides a significant competitive advantage for developing next-generation diagnostic AI tools.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Demand is exceptionally high, driven by the AI in Medical Imaging market's rapid expansion at a 25.8% CAGR, creating an urgent need for high-quality, clinically-validated imaging datasets. [7]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — This clinical-stage biopharma's core business is developing an anti-cancer drug; the data from its multi-national clinical trials, including medical imaging, is a highly valuable by-product not currently being sold.
- Deep Qualification80
⚠ needs review — AbilityPharma is a biopharmaceutical company whose core business is drug development, not data sales. The clinical trial data it generates, which includes medical imaging, is a high-value byproduct. However, this data is subject to severe restrictions due to its nature as sensitive patient health information, and the company's clinical trial registration explicitly states no plan to share individual participant data. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence points to a structured dataset of medical images from a completed Phase 2b clinical trial, offering diagnostic AI developers a rare source of curated data for a specific cancer type.
Industrial data
This indicates the existence of pre-clinical, time-series data from oncology research models, valuable for AI companies developing predictive tools for drug efficacy.
Regulatory records
This textual evidence confirms the holder's strategic focus on developing drugs for oncological unmet needs, providing crucial context that validates the targeted nature and commercial relevance of their data assets.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Abilitypharma Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market size is expected to be worth around US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8% (source: Exactitude Consultancy). Investment score 67.3/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Starseq — Medical Imaging Dataset Opportunity
View opportunity →healthcareIcentia — Medical Imaging Dataset Opportunity
View opportunity →healthcareEumediq — Medical Imaging Dataset Opportunity
View opportunity →